Summary:
Click image to enlargeA phase III randomized, double-blind, placebo-controlled parallel-group trial to examine the efficacy and safety of BI 425809 once daily over a 26-week treatment period in patients with schizophrenia.
Qualified Participants Must:
• Male or female patients who are 18-50 years of age at the time of consent.
•
Have a study partner with at least 1 x /week contact
•
Medically stable for at least 12 weeks
Qualified Participants May Receive:
If you qualify and decide to participate you will be paid $150 for the study visits you complete.